The acceptance of the Marketing Authorization Application by the European Medicines Agency is a significant regulatory milestone for Autolus Therapeutics. It indicates progress in the development and potential commercialization of Obecabtagene Autoleucel, which could lead to increased investor confidence and a positive impact on the company's stock price in the short term.